JP6830437B2 - 疾患を処置するための遺伝子改変された細胞、組織および臓器 - Google Patents

疾患を処置するための遺伝子改変された細胞、組織および臓器 Download PDF

Info

Publication number
JP6830437B2
JP6830437B2 JP2017530596A JP2017530596A JP6830437B2 JP 6830437 B2 JP6830437 B2 JP 6830437B2 JP 2017530596 A JP2017530596 A JP 2017530596A JP 2017530596 A JP2017530596 A JP 2017530596A JP 6830437 B2 JP6830437 B2 JP 6830437B2
Authority
JP
Japan
Prior art keywords
cells
genetically modified
hla
cell
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017530596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500897A5 (https=
JP2018500897A (ja
Inventor
バーナード ジェイ． へリング，
バーナード ジェイ． へリング，
クリストファー ブルラク，
クリストファー ブルラク，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2018500897A publication Critical patent/JP2018500897A/ja
Publication of JP2018500897A5 publication Critical patent/JP2018500897A5/ja
Application granted granted Critical
Publication of JP6830437B2 publication Critical patent/JP6830437B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2017530596A 2014-12-10 2015-12-10 疾患を処置するための遺伝子改変された細胞、組織および臓器 Active JP6830437B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462090037P 2014-12-10 2014-12-10
US62/090,037 2014-12-10
US201562253493P 2015-11-10 2015-11-10
US62/253,493 2015-11-10
PCT/US2015/065029 WO2016094679A1 (en) 2014-12-10 2015-12-10 Genetically modified cells, tissues, and organs for treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020026602A Division JP2020096632A (ja) 2014-12-10 2020-02-19 疾患を処置するための遺伝子改変された細胞、組織および臓器

Publications (3)

Publication Number Publication Date
JP2018500897A JP2018500897A (ja) 2018-01-18
JP2018500897A5 JP2018500897A5 (https=) 2019-01-24
JP6830437B2 true JP6830437B2 (ja) 2021-02-17

Family

ID=56108194

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017530596A Active JP6830437B2 (ja) 2014-12-10 2015-12-10 疾患を処置するための遺伝子改変された細胞、組織および臓器
JP2020026602A Pending JP2020096632A (ja) 2014-12-10 2020-02-19 疾患を処置するための遺伝子改変された細胞、組織および臓器
JP2021097515A Pending JP2021126129A (ja) 2014-12-10 2021-06-10 疾患を処置するための遺伝子改変された細胞、組織および臓器
JP2021114775A Pending JP2021166542A (ja) 2014-12-10 2021-07-12 疾患を処置するための遺伝子改変された細胞、組織および臓器

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020026602A Pending JP2020096632A (ja) 2014-12-10 2020-02-19 疾患を処置するための遺伝子改変された細胞、組織および臓器
JP2021097515A Pending JP2021126129A (ja) 2014-12-10 2021-06-10 疾患を処置するための遺伝子改変された細胞、組織および臓器
JP2021114775A Pending JP2021166542A (ja) 2014-12-10 2021-07-12 疾患を処置するための遺伝子改変された細胞、組織および臓器

Country Status (9)

Country Link
US (6) US9888673B2 (https=)
EP (1) EP3229586B1 (https=)
JP (4) JP6830437B2 (https=)
KR (1) KR102656470B1 (https=)
CN (3) CN116059378A (https=)
AU (5) AU2015360502A1 (https=)
CA (1) CA2969847A1 (https=)
HK (1) HK1245010A1 (https=)
WO (1) WO2016094679A1 (https=)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
SG11201602232UA (en) 2013-09-24 2016-04-28 Giner Inc System for gas treatment of a cell implant
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP2018509994A (ja) * 2015-03-27 2018-04-12 エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 患者選択的アフェレシス
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
KR20230110373A (ko) * 2016-06-14 2023-07-21 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직,및 장기
BR112019001344A2 (pt) 2016-07-26 2019-04-30 The University Of North Carolina At Chapel Hill tolerância imunológica mediada por vetor no olho
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018075830A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
AU2017361260B2 (en) 2016-11-15 2023-06-08 Giner, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3568474A1 (en) * 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
KR20190109440A (ko) * 2017-01-30 2019-09-25 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 줄기 세포 이식을 위한 비-유전독성 컨디셔닝 레지멘
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
CA3094322A1 (en) * 2017-03-20 2018-09-27 Washington University Cells and methods of uses and making the same
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018177441A1 (en) 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
CN108588126B (zh) * 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
KR102746223B1 (ko) 2017-04-20 2024-12-27 이제네시스, 인크. 유전자 변형 동물의 생성 방법
CN110831656A (zh) 2017-05-04 2020-02-21 吉纳生命科学公司 稳健的可植入气体递送装置和方法、系统以及包括该装置的装置
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
MX2019014578A (es) * 2017-06-21 2020-12-01 Timothy A Bertram Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
US10391156B2 (en) * 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
CN112236514A (zh) 2017-12-05 2021-01-15 塞利亚德股份公司 改善细胞过继转移的持久性的组合物和方法
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3510861A3 (en) 2017-12-22 2019-09-25 Avantea SRL Hypoallergenic food and medical products from genome edited livestock
CN108220294A (zh) * 2018-02-11 2018-06-29 南京医科大学 CRISPR/Cas9载体组合及其在基因敲除中的应用
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
CN108330130B (zh) * 2018-03-14 2021-09-07 中国食品药品检定研究院 sgRNA及其制备的Gal抗原缺失兔子模型和应用
JP7477457B2 (ja) * 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
CN109207429A (zh) * 2018-05-04 2019-01-15 窦科峰 永生化的α-1,3-半乳糖转移酶基因敲除猪肝细胞系及其制备方法和应用
CN108588123A (zh) * 2018-05-07 2018-09-28 南京医科大学 CRISPR/Cas9载体组合在制备基因敲除猪的血液制品中的应用
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
MX2021003866A (es) 2018-10-05 2021-09-08 Xenotherapeutics Inc Productos y metodos de xenotransplante.
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3866815B1 (en) 2018-10-19 2024-05-01 Regents Of The University Of Minnesota Transplant tolerance induction with carbodiimide treated tolerizing vaccine
CA3117098A1 (en) * 2018-10-19 2020-04-23 The General Hospital Corporation Compositions and methods for treatment of liver disease
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
WO2020131717A1 (en) * 2018-12-16 2020-06-25 Figene, Llc Therapeutic uses of gene edited fibroblasts
AU2020204994A1 (en) * 2019-01-03 2021-07-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
US20220175781A1 (en) * 2019-03-08 2022-06-09 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US20220214333A1 (en) * 2019-04-16 2022-07-07 Regents Of The University Of Minnesota Biomarker for transplantation tolerance induced by apoptotic donor leukocytes
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110079529A (zh) * 2019-04-28 2019-08-02 成都美杰赛尔生物科技有限公司 用于靶向敲除人NKG2A/KLRC1基因的sgRNA、表达载体、试剂盒及其用途
WO2020228039A1 (en) * 2019-05-16 2020-11-19 Egenesis, Inc. Cells, tissues, organs, and/or animals having one or more modified genes for enhanced xenograft survival and/or tolerance
KR20220033468A (ko) * 2019-05-16 2022-03-16 이제네시스, 인크. 강화된 이종이식편 생존 및/또는 내성을 위한 하나 이상의 변형된 유전자를 갖는 세포, 조직, 장기 및/또는 동물
WO2020228043A1 (en) * 2019-05-16 2020-11-19 Egenesis, Inc. Cells, tissues, organs, and/or animals having one or more modified genes for enhanced xenograft survival and/or tolerance
WO2021072778A1 (en) * 2019-10-18 2021-04-22 Egenesis, Inc. Cells, tissues, organs, and/or animals having one or more modified genes for enhanced xenograft survival and/or tolerance
WO2021072777A1 (en) * 2019-10-18 2021-04-22 Egenesis, Inc. Cells, tissues, organs, and/or animals having one or more modified genes for enhanced xenograft survival and/or tolerance
AU2020288829A1 (en) * 2019-06-04 2021-12-02 Nkarta, Inc. Combinations of engineered natural killer cells and engineered T cells for immunotherapy
CN110373390A (zh) * 2019-06-10 2019-10-25 云南农业大学 一种异种器官移植基础供体猪的构建方法
CN110373391A (zh) * 2019-06-10 2019-10-25 云南农业大学 一种适合心脏异种移植供体猪的构建方法
EP3760718A1 (en) * 2019-07-04 2021-01-06 Medizinische Hochschule Hannover Tissue for use as allogeneic or xenogeneic transplant and method for its production
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
KR20220084296A (ko) * 2019-10-22 2022-06-21 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 형질전환 돼지, 이의 제조 방법 및 용도, 그리고 인간 면역계 마우스를 제조하는 방법
CA3164008A1 (en) * 2020-01-07 2021-07-15 Hangzhou Qihan Biotechnology Co., Ltd. Methods and compositions for production of xenogeneic islet cells and treatment of insulin-resistant or -deficient conditions with the same
WO2021144574A1 (en) * 2020-01-14 2021-07-22 Pig Improvement Company Uk Limited Gene editing of unfertilized porcine and bovine oocytes
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
WO2021241658A1 (ja) * 2020-05-26 2021-12-02 株式会社ヘリオス 低免疫原性細胞
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
CN111955422A (zh) * 2020-08-21 2020-11-20 五邑大学 一种可用于异种器官移植的供体猪的构建方法
CN111979243B (zh) * 2020-08-24 2023-05-23 大连大学 利用CRISPR/Cas9系统构建TAP基因缺失的猪T2细胞的方法
KR20230066376A (ko) * 2020-09-07 2023-05-15 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 이종이식을 위한 유전자 변형
WO2022095902A1 (en) * 2020-11-03 2022-05-12 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
US20240358761A1 (en) * 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
US20230203176A1 (en) * 2021-09-17 2023-06-29 Novartis Ag Methods For Prevention Of Graft Rejection In Xenotransplantation
WO2023064604A1 (en) * 2021-10-14 2023-04-20 New York Stem Cell Foundation, Inc. Modified cells and methods of use thereof
TW202325844A (zh) * 2021-11-03 2023-07-01 中國大陸商杭州啟函生物科技有限公司 增強免疫療法的系統和方法
WO2023081831A2 (en) * 2021-11-05 2023-05-11 Diabetes-Free, Inc. Methods and compositions for immune tolerance to aav antigens and transgene products in gene therapy
CA3251543A1 (en) * 2022-02-16 2023-08-24 President And Fellows Of Harvard College HYPOIMMUNOGENEOUS BETA CELLS AND THEIR PRODUCTION PROCESSES
US20240294869A1 (en) * 2023-03-03 2024-09-05 Nugift Medical Llc Pig xenotransplants into humans without chronic immunosuppression
AU2024317934A1 (en) * 2023-08-02 2026-02-19 Joslin Diabetes Center, Inc. Ribosomal remodeling in diabetes

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4702907A (en) 1983-08-09 1987-10-27 Cornell Research Foundation, Inc. Process for inducing selective immunosuppression of antibodies
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1178786B (it) 1984-12-21 1987-09-16 Assorenti Analoghi retro-inverso parzialmente modificati della neurotensina
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69331778T2 (de) 1992-01-08 2002-11-14 The General Hospital Corp., Boston Induzierte toleranz gegen transplantate
US6916654B1 (en) 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5849991A (en) 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6156306A (en) 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JPH11510698A (ja) * 1995-08-04 1999-09-21 ザ ジェネラル ホスピタル コーポレイション トランスジェニックブタ及びヒトｈｌａ遺伝子を有するブタ細胞
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
EP0892643B2 (en) 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1997047321A1 (en) * 1996-06-14 1997-12-18 The Johns Hopkins University School Of Medicine Use of chimeric vaccinia virus complement control proteins to inhibit complement
US6339069B1 (en) 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
WO1998042838A1 (en) 1997-03-25 1998-10-01 Morphogenesis, Inc. Universal stem cells
BR9809641A (pt) 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US6825395B1 (en) * 1997-07-14 2004-11-30 Nippon Meat Packers, Inc. Transgenic non-human mammals expressing the human complement inhibitor (DAF/CD55)
US6521448B1 (en) * 1997-08-19 2003-02-18 Diacrin, Inc. Porcine MHC class I genes and uses thereof
AU748443B2 (en) 1998-02-04 2002-06-06 General Hospital Corporation, The Costimulatory blockade and mixed chimerism in transplantation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
WO2000037102A2 (en) * 1998-12-19 2000-06-29 Ml Laboratories Plc Improvement of tolerance to a xenograft
CA2361191A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
US20020012660A1 (en) 1999-03-04 2002-01-31 Alan Colman Method of preparing a somatic cells for nuclear transfer
WO2001015521A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
CN1377225A (zh) * 1999-09-13 2002-10-30 马萨诸塞大学 使用来自分化细胞的供体细胞或细胞核克隆猪以及多能猪的生成
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
KR100417566B1 (ko) 1999-11-19 2004-02-05 한국생명공학연구원 체세포 핵치환 복제수정란의 대량생산방법
CA2392615A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
US20020006403A1 (en) 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
US20010051156A1 (en) 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
EP1322383B9 (en) 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2001297523B2 (en) 2000-11-17 2007-01-18 Sab, Llc Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
AR033022A1 (es) 2001-03-30 2003-12-03 Dow Agrosciences Llc Genes biosinteticos para la produccion de insecticida de butenilespinosina
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US7166278B2 (en) 2001-04-30 2007-01-23 Rbc Biotechnology, Inc. Modified organs and cells for xenotransplantation
US7780993B2 (en) 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
AU2002350039A1 (en) 2001-10-29 2003-05-12 Renovis, Inc. Method for isolating cell-type specific mrnas
AU2002357110A1 (en) 2001-12-07 2003-07-09 The Ohio State University Research Foundation Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder
US20030118568A1 (en) 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
US7115796B2 (en) 2002-05-06 2006-10-03 Animal Technology Institute Transgenic pig containing heat shock protein 70 transgene
FR2840307B1 (fr) 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
US7580532B2 (en) 2002-08-06 2009-08-25 Lg Electronics Inc. Multi-channel pulse width modulation apparatus
DK1534819T3 (da) 2002-08-21 2010-04-19 Revivicor Inc Griselignende dyr, som mangler enhver ekspression af funktionel alfa-1,3-galactosyltransferase
IL165425A0 (en) 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2005006949A2 (en) 2003-07-07 2005-01-27 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CN1922316B (zh) 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
AU2005223617A1 (en) 2004-03-17 2005-09-29 Revivicor, Inc. Tissue products from animals lacking functional alpha 1,3 galactosyl transferase
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US20060148080A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Methods for supporting and producing human cells and tissues in non-human mammal hosts
US8889365B2 (en) 2005-03-16 2014-11-18 Rutgers, The State University Of New Jersey Methods and kit for detecting breast cancer
DK2341149T3 (en) 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
WO2007053661A2 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
AU2006337093B2 (en) 2005-12-22 2013-03-14 Opko Pharmaceuticals, Llc. Compositions and methods for regulating complement system
US20070237826A1 (en) 2006-04-05 2007-10-11 Rao Kollipara K Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
WO2007124751A2 (en) 2006-05-01 2007-11-08 Aarhus Universitet An animal model and a method for producing an animal model
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
DK2426220T3 (en) 2006-05-19 2016-09-26 Dupont Nutrition Biosci Aps Labeled microorganisms, and methods for labeling
US9006510B2 (en) 2006-06-29 2015-04-14 Mayo Foundation For Medical Education And Research Genetically modified heart valve xenografts
DK2134846T3 (en) 2007-03-07 2018-11-26 Univ Aarhus Transgenic swine as a model for Alzheimer's disease
US7750449B2 (en) 2007-03-13 2010-07-06 Micron Technology, Inc. Packaged semiconductor components having substantially rigid support members and methods of packaging semiconductor components
AU2008233256B2 (en) 2007-03-28 2013-06-27 The Curators Of The University Of Missouri Transgenic animal models of disease
MX2010005099A (es) 2007-11-09 2010-05-27 Novartis Ag Usos de anticuerpos anti-cd40.
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
EP2077329A1 (en) 2008-01-04 2009-07-08 MWM Biomodels GmbH Transgenic pig with altered incretin function
CA2712989C (en) 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
EP2184297A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
ES2767881T3 (es) * 2009-08-14 2020-06-18 Revivicor Inc Cerdos multi-transgénicos para el tratamiento de diabetes
US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
HUE049849T2 (hu) 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
WO2011139488A2 (en) 2010-05-06 2011-11-10 Mayo Foundation For Medical Education And Research Methods and materials for reducing cardiac xenograft rejection
US20130177577A1 (en) * 2010-07-12 2013-07-11 Dana-Farber Cancer Institute, Inc. Nlrc5 as a target to intervene mhc class 1-mediated immune responses
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
TWM402396U (en) 2010-11-05 2011-04-21 Holimay Corp Motor mask for the water discharge device for cooling or air-conditioning device
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2680636T3 (es) 2011-02-14 2018-09-10 Revivicor Inc. Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos
JP5458188B2 (ja) 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
CA3205636A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
WO2012145632A1 (en) 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
HUE038848T2 (hu) 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
JP2014519340A (ja) * 2011-06-16 2014-08-14 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． バイオマーカー組成物および方法
CN103796681B (zh) * 2011-06-30 2018-07-20 建新公司 T细胞活化的抑制剂
KR101307196B1 (ko) 2011-07-15 2013-09-12 국립대학법인 울산과학기술대학교 산학협력단 미세 세포 배양 장치
CN102911270A (zh) 2011-08-05 2013-02-06 浙江大学 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
WO2013063076A1 (en) 2011-10-25 2013-05-02 Indiana University Research & Technology Corporation Compositions for and methods of modulating complications, risks and issues with xenotransplantation
SMT201900478T1 (it) * 2011-10-28 2019-09-09 Regeneron Pharma Topi con complesso maggiore di istocompatibilita' geneticamente modificati
UA115772C2 (uk) 2011-12-16 2017-12-26 Таргітджин Байотекнолоджиз Лтд Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
FI2838548T3 (fi) 2012-04-17 2023-10-02 Univ Washington Through Its Center For Commercialization HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt
CN102851279B (zh) 2012-05-04 2013-10-16 东北农业大学 猪rosa26特异性整合位点及其应用
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9883939B2 (en) 2012-05-08 2018-02-06 The General Hospital Corporation Reducing immunogenicity of xenogeneic transplant tissues
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
KR101329411B1 (ko) 2012-05-31 2013-11-14 주식회사 엘지생활건강 피부투과성 펩타이드
AU2013293270B2 (en) 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods
FI2892330T3 (fi) 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
US20140115728A1 (en) 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
US20140120152A1 (en) 2012-10-31 2014-05-01 Northwestern University Scaffold Delivery of Immune Suppressors and Transplant Material for Control of Transplant Rejection
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
IL239344B2 (en) 2012-12-12 2024-06-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
WO2014093709A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
CN104046593A (zh) 2013-03-14 2014-09-17 浙江大学 一种低免疫原性的人细胞及其制备方法
US20160138027A1 (en) 2013-03-14 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
RU2662932C2 (ru) 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
CN105683376A (zh) 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
EP3003350B1 (en) * 2013-05-27 2018-02-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Targeted modulation of macrophages
AU2014273082B2 (en) 2013-05-29 2018-11-08 Cellectis A method for producing precise DNA cleavage using Cas9 nickase activity
JP6195474B2 (ja) 2013-05-31 2017-09-13 ギガフォトン株式会社 極端紫外光生成装置及び極端紫外光生成システムにおけるレーザシステムの制御方法
CN105492611A (zh) 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
MX374532B (es) 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
WO2014204723A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
EP3019595A4 (en) 2013-07-09 2016-11-30 THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
EP3666892A1 (en) 2013-07-10 2020-06-17 President and Fellows of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
WO2015006774A2 (en) 2013-07-12 2015-01-15 Oms Investments, Inc. Plants comprising events pp009-401, pp009-415, and pp009-469, compositions, sequences, and methods for detection thereof
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
CN120574876A (zh) 2013-08-22 2025-09-02 纳幕尔杜邦公司 使用向导rna/cas内切核酸酶系统的植物基因组修饰及其使用方法
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
DE102013111099B4 (de) 2013-10-08 2023-11-30 Eberhard Karls Universität Tübingen Medizinische Fakultät Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
JP2016538001A (ja) 2013-11-28 2016-12-08 ホライズン・ジェノミクス・ゲーエムベーハー 体細胞半数体ヒト細胞株
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
JP2017512481A (ja) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
TWI530276B (zh) 2014-07-08 2016-04-21 原相科技股份有限公司 具去噪功能之生理偵測模組及其生理偵測方法
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CA2965550A1 (en) * 2014-10-22 2016-04-28 Indiana University Research & Technology Corporation Triple transgenic pigs suitable for xenograft
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN104789592A (zh) 2015-03-19 2015-07-22 中国食品药品检定研究院 一种制备α-1,3GT基因敲除的非人哺乳动物的方法及应用
CN107921148A (zh) 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US20180172683A1 (en) 2015-06-22 2018-06-21 University Of Southern California Methods for analyzing the interaction between a target protein and a ligand
WO2016210280A1 (en) 2015-06-26 2016-12-29 Indiana University Research & Technology Corporation Transgenic pigs with genetic modifications of sla
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
BR112018012235A2 (pt) 2015-12-18 2018-12-04 Sangamo Therapeutics Inc rompimento alvejado do receptor de células de mhc
US9570114B1 (en) 2016-01-15 2017-02-14 HGST Netherlands B.V. Laminated film-packed hard disk drive for hermetic sealing
US20170251646A1 (en) 2016-03-01 2017-09-07 Indiana University Research And Technology Corporation Transgenic pigs lacking one or more cellular transport genes
KR20230110373A (ko) 2016-06-14 2023-07-21 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직,및 장기
JP2020505025A (ja) 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
JP2021513367A (ja) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof

Also Published As

Publication number Publication date
US10278372B2 (en) 2019-05-07
JP2020096632A (ja) 2020-06-25
EP3229586B1 (en) 2025-07-30
AU2022201296A1 (en) 2022-03-17
KR20170092692A (ko) 2017-08-11
US20180092338A1 (en) 2018-04-05
WO2016094679A1 (en) 2016-06-16
US12465029B2 (en) 2025-11-11
US20200352142A1 (en) 2020-11-12
AU2022201307B2 (en) 2023-04-13
JP2018500897A (ja) 2018-01-18
US20220104467A1 (en) 2022-04-07
CN107249318A (zh) 2017-10-13
CN116059378A (zh) 2023-05-05
JP2021166542A (ja) 2021-10-21
AU2022201296B2 (en) 2025-08-14
KR102656470B1 (ko) 2024-04-09
AU2023204606A1 (en) 2023-08-03
AU2022201329B2 (en) 2023-02-23
US20190254265A1 (en) 2019-08-22
US9888673B2 (en) 2018-02-13
AU2015360502A1 (en) 2017-06-29
JP2021126129A (ja) 2021-09-02
CN113699116A (zh) 2021-11-26
AU2022201329A1 (en) 2022-03-24
EP3229586A1 (en) 2017-10-18
HK1245010A1 (zh) 2018-08-24
US20260041072A1 (en) 2026-02-12
US10993419B2 (en) 2021-05-04
AU2022201307A1 (en) 2022-03-24
EP3229586A4 (en) 2018-10-24
US11234418B2 (en) 2022-02-01
CA2969847A1 (en) 2016-06-16
US20160165861A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
US12465029B2 (en) Genetically modified cells, tissues, and organs for treating disease
AU2017285224B2 (en) Genetically modified cells, tissues, and organs for treating disease
EP1437404A1 (en) Tailor-made multifunctional stem cells and utilization thereof
KR20180091821A (ko) 유전적 상보성에 의한 인간화 car t-세포 및 혈소판의 조작방법
US20220061279A1 (en) Genetically modified cells, tissues, and organs for treating disease
US20240277776A1 (en) Hypoimmune cells
Butler Nuclease-based editing in the porcine genome: a strategy to facilitate porcine-to human xenotransplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200929

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200929

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201126

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210126

R150 Certificate of patent or registration of utility model

Ref document number: 6830437

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250